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Nuclear factor-kappaB (NF-𝜅B)/interleukin (IL-6) pathway links chronic inflammation to colitis associated cancer (CAC). In this
study, we examined the dynamic temporal changes of the NF-𝜅B/IL-6 pathway during the procession of experimental CACmouse
model. Mice were sacrificed after induction for 14, 16, 18, and 22 weeks for the examination of tumor burden, inflammation degree,
and protein level of NF-𝜅B and IL-6 in bowel tissues.The results showed that tumor burden and inflammation severity in the bowels
were gradually increased over the observed time-points.The expressions of IL-6 and NF-𝜅B proteins were gradually increased after
induction of dysplastic lesions over times. These data provide new information on the dynamic temporal changes of NF-𝜅B/IL-6
pathway in relation to CAC development that may be relevant in the design of future investigations of therapeutic interventions to
effectively target CAC processes.
1. Introduction
Patients with ulcerative colitis (UC) are at increased risk for
colorectal cancer, a phenomenon with the largest fraction
being attributed to chronic inflammation [1, 2].
Growing evidence supports a role for proinflammatory
mediators present in the tumor microenvironment in the
pathogenesis of colitis associated colorectal cancer (CAC)
[3]. Interleukin IL-6 is a pleiotropic cytokine with potent
functions in promoting inflammation and neoplastic trans-
formation and is involved in the development of CAC [4–7].
It has been found that the expression of IL-6 is increased and
its expression level is correlated with the severity of disease in
UC [8–10]. The promoting effect of IL-6 on the development
of CAC has also been studied [3, 11–13]. Grivennikov and
colleagues [12] have demonstrated that IL-6 exerts a strong
promoting effect on the development of CAC in mice dosed
with a low amount of chemical inflammation inducing regent
dimethylhydrazine (DSS), whereas blocking of IL-6 signal by
injecting IL-6 receptor antibody can successfully suppress the
intestinal inflammation [14, 15] and then CAC [6, 16]. Further
evidence suggests that the genes that encode IL-6 are under
the control of transcriptional nuclear factor-kappa B (NF-𝜅B)
[3, 17]. In Grivennikov’s study [12], the authors have demon-
strated that the activation of NF-𝜅B increases the production
of IL-6 by lamina propria myeloid cells, while the increase of
IL-6 protects the premalignant intestinal epithelial cell from
apoptosis that is largely mediated by the transcription factor
Stat3 [12]. Thus, it is proposed the NF-𝜅B-IL-6-Stat3 cascade
is an essential stimulator for the proliferation and survival
of precancerous cells in the context of chronic inflammation
[12]. Interestingly, a study has shown that the DSS-evoked
intestinal inflammation and CAC are significantly inhibited
by the inactivation of IKK𝛽 (a protein kinase responsible for
NF-𝜅B activation) in mice [18]. Therefore, current evidence
strongly suggests that NF-𝜅B/IL-6 pathway is a key player
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in linking chronic inflammation to CAC [19, 20]. However,
dynamic of the NF-𝜅B/IL-6 pathway during the procession
of CAC has not been well characterized.
In viewof these observations, we therefore performed this
study to evaluate the dynamic temporal changes ofNF-𝜅B/IL-
6 pathway in relation to the procession of experimental CAC
in mice.
2. Materials and Methods
2.1. Animals. Twenty-nine specific-pathogen-free ICR male
mice aged 5 weeks (median weight of 35 g) were purchased
from Shanghai Super-B&K Laboratory Animal Corp., Ltd.,
China, and housed in a specific-pathogen-free environment
and fed with commercial pellets. All experiments were
approved by the Local Animal Welfare Committee of
Zhengzhou University.
CAC in mice was inducedby 1.2-dimethylhydrazine
(DMH) plus dextran sulfate sodium (DSS) administration as
previous reports [21, 22]. Briefly, the mice were i.p. injected
with 25mg/kg DMH (Aladdin Chemistry, Shanghai, China,
MW 133.02) once weekly and kept on regular diet and
water for 7 days and then received 1% DSS solution (MP
Biomedicals LLC, Illkirch Cedex, France, MW 50,000) for 7
days; total 10 more DSS treatment cycles were applied until
the experimental terminal (after induction for 22 weeks).
2.2. Tumor Number Counts and Inflammation Degree Analy-
sis. Mice were sacrificed after induction for 14, 16, 18, and 22
weeks. Large bowels were opened longitudinally, flushed with
saline, and macroscopic tumors were counted.
Then, bowel tissues were divided into two parts, one
part for the protein (western blotting) study and another
for the histological examination at the Department of
Pathology. Embedded colorectal tissues were cut in 4𝜇m
thickened serial sections and stained with hematoxylin and
eosin (H&E) staining sections. Severity of inflammation was
graded as light, moderate, and high according to the inflam-
matory cell infiltration [23] by experienced pathologists at
the Department of Pathology, the 2nd Affiliated University
Hospital of Zhengzhou University, and reviewed by Senior
Pathologist Dr. JR.
2.3. Immunohistochemistry (IHC) of IL-6 and NF-𝜅B. IHCs
for IL-6 and NF-𝜅B were performed with Vectastain Elite
ABC Kit (Vector Laboratories Inc., Burlingame, CA, USA)
according to the manufacturer’s instructions and our pub-
lished method [24]. The following primary antibodies were
used: rabbit anti-IL-6 polyclonal antibody (working dilution
1 : 100, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA)
and rabbit anti-NF-𝜅B polyclonal antibody (working dilution
1 : 100, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA).
Antibodies were incubated at 4∘C over night. 3-Amino-
9-ethylcarbazole (AEC, Vector Laboratories, Burlingame,
CA, USA) was used as chromogen and slides were slightly
counterstained with Mayer’s hematoxylin. Negative control
slides for IHCs were performed routinely: (1) primary anti-
bodies were substituted with the isotype-matched control
antibodies; (2) secondary antibody was substituted with
phosphate buffered saline (PBS). Both H&E and IHC stained
slideswere observed under lightmicroscopy (DM2000, Leica
Microsystems, Wetzlar, Germany).
Morphometric evaluation was performed in both the
stroma and the epithelium in stained slide. In the stroma
the density of IL-6 and NF-𝜅B positive cells in 3 fields with
the most abundant positive cells was graded according to the
method we published previously [25]. The average values per
slide were used for statistical analysis.
2.4. Western Blotting for IL-6 and NF-𝜅B. Tissue samples
were homogenized in a standard RIPA buffer, unless stated
otherwise, with a cocktail of protease and phosphatase
inhibitors. Cytoplasmic and nuclear proteins were pre-
pared using NE-PER kit according to the manufacturer’s
instructions. Lysates were separated on a 10–15% SDS-
polyacrylamide gel and proteins were transferred to PVDV
membrane. Membranes were blocked in PBST buffer con-
taining 5% skim milk for 1 hour at room temperature
and probed with primary antibodies and secondary HRP-
conjugated antibodies. Membranes were developed using
ECL western blot detection reagent.
2.5. Statistical Analysis. Results were expressed as mean ±
SEM (standard error of the mean) unless otherwise stated.
Statistical significancewas evaluated by theMann-WhitneyU
test and the Kruskal-Wallis test. The correlation coefficients
between overall bowel tumor number and the densities of
IL-6 and NF-𝜅B positive cells were determined by Spearman
correlation analyses. Values of 𝑃 < 0.05 or 𝑃 < 0.01 were
considered significant.
3. Results
3.1. Tumor Incidence and Inflammation Degree in Male ICR
Mice at Different Time-Points. Tumors were observed in the
colorectal mucosa and the number of tumors was increased
over observed times (Figure 1). The size of macroscopic
tumorswas gradually increased over times (14weeks versus 16
weeks versus 18 weeks versus 22 weeks: 0.5 ± 0.23mm versus
3.13 ± 1.5mm versus 3.93 ± 1.83mm versus 4.42 ± 1.20mm,
𝑃 < 0.01, the Kruskal-Wallis test). Normal histological
appearance was shown in the control (Figure 2(a)); dysplastic
lesion was observed in CAC mice. Dysplastic lesion in the
colorectal mucosa after induction for 14 weeks was at a low
grade (Figure 2(b)) and it was gradually increased over time
(Figure 2(c) for the 16weeks, Figure 2(d) for the 18weeks) and
finally became cancerous lesion after induction for 22 weeks
(Figure 2(e)).
The administration of DMH and DSS also evoked a
strong inflammation in the colorectal mucosa; it was started
after induction for 14 weeks and through the experimental
terminal (for 22 weeks). The grading score of inflammation
was increased after induction for 14 weeks and through the
experimental terminal (see Figure 3).
3.2. The Changes of IL-6 and NF-𝜅B Positive Cell Densities
in the Tumor Microenvironment during the Processing of
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Figure 1: Increased tumor number in the bowels over examined
time-points. The data showed that the overall tumor number in the
bowels after the administration of DMH and DSS was gradually
increased after induction for 14 weeks and through 22 weeks.
CAC. The expressions of IL-6 and NF-𝜅B in dysplastic lesion
during the procession of CAC were examined with IHC
over different time-points. The results showed that IL-6
immunoreactivity was observed both in the transformed
epithelial cells (arrow head pointed in Figure 4(a)) and in
the tumor stroma cells (arrow pointed in Figure 4(a)). After
induction for 22 weeks, the CAC neoplastic epithelium was
strongly positive for IL-6 (arrow head pointed in Figure 4(a)).
When the density of IL-6 positive cells was graded, it was
shown that the increase of IL-6 positive cell density was
started after induction for 14 weeks, became even higher
after induction for 16 and 18 weeks, and reached the highest
level after induction for 22 weeks (experimental terminal) in
both transformed epithelium (Figure 4(c)) and tumor stroma
(Figure 4(d)).
The expression of NF-𝜅B in the tumor tissues was in
the same change pattern as IL-6. NF-𝜅B immunoreactivity
was detected both in the transformed CAC cells (arrow head
pointed in Figure 4(b)) and in the tumor stroma cells (arrow
pointed in Figure 4(b)). The density of NF-𝜅B positive cells
was also shown in an increased trend in both transformed
epithelium (Figure 4(e)) and tumor stroma (Figure 4(f)) over
the observed time-points.
3.3. Expression of IL-6 and NF-𝜅B Proteins in the Tumor
Tissues over the Observed Time-Points. The expression of IL-
6 andNF-𝜅B proteins in the tumor tissues was examinedwith
western blotting.The results confirmed the IHC observations
and demonstrated increased expression of NF-𝜅B and IL-6
proteins in the tumor tissues (see Figure 4(g)) that was started
after induction for 14 weeks and became more significant in
the experimental terminal (after induction for 22 weeks).
3.4. Correlations. In order to further address the relationship
between overall macroscopic tumor number in the bowel and
the densities of NF-𝜅B and IL-6 in the tumor tissues, we
performed correlation analyses. CACmice from all observed
time-points were included in the correlation analyses. As
results present in Table 1, the analysis data showed that both
Table 1: Correlations between tumor number and densities of IL-6
and NF-𝜅B positive cells.
Spearman 𝛾 𝑃 value
Tumor number versus intraepithelial IL-6 0.5634 0.0078
Tumor number versus stromal IL-6 0.6359 0.0019
Tumor number versus intraepithelial NF-𝜅B 0.4466 0.0287
Tumor number versus stromal NF-𝜅B 0.5827 0.0028
of NF-𝜅B and IL-6 in the stroma and dysplastic epithelium
were positively associated with the overall tumor number in
the bowel (𝑃 < 0.01 ∼ 0.05; see Table 1).
4. Discussion
There are growing evidences to support the view that the
activation of NF-𝜅B/IL-6 pathway is involved in the devel-
opment of CAC [12, 17, 18, 20, 26]. This study used an CAC
mouse model to examine the dynamic temporal changes
of NF-𝜅B/IL-6 pathway in relation to the procession of
experimental CAC inmice. Our findings showed an elevation
of NF-𝜅B/IL-6 expression that occurs over the examined
time-points (after induction for 14–22 weeks) in association
with the rapid increased macroscopic tumor number and
dysplastic lesion degree in colitis mice. These data contribute
to the growing evidence on the association between intestinal
inflammation and CAC and provide new insights into the
importance of NF-𝜅B/IL-6 pathway in relation to colitis
associated carcinogenesis.
The link between chronic inflammation and the develop-
ment/progression of human cancers has beenwell recognized
for several decades [27–29]; recent findings support the fact
that NF-𝜅B-regulated inflammatory cytokines contribute to
the pathogenesis of chronic inflammation and then to the
development of CRC [30, 31]. In this study, we have found
that the expressions of NF-𝜅B and IL-6 were synchronously
increased in the tumor tissues and accompanied with the
process of CAC inmice over the examined time-points. After
induction for 14 weeks, inflammation characterization was
observed; the number of macroscopic tumors and the degree
of dysplastic lesions in the bowel were gradually increased
over the observed time-points. Furthermore, IHC analysis
revealed that increased densities of IL-6 and NF-𝜅B positive
cells were observed in both the transformed epithelium and
the tumor stroma, which are consistent with the findings
in similar CAC mouse models reported by other groups
[4, 12, 18]. In this study, we have observed that the expression
of both NF-𝜅B and IL-6 was in the dysplastic epithelial cells;
this may suggest that NF-𝜅B expressed in the transformed
cell also regulates the production of IL-6 and contributes
to the elevation of NF-𝜅B and IL-6 in dysplastic lesions.
Finally, our data showed a strong relationship between overall
tumor number and NF-𝜅B/IL-6 positive cells at all examined
time-points and indicated that NF-𝜅B/IL-6 pathway may
contribute to the transformation of CAC in this colitis mouse
model.
The exact mechanisms behind the protumor effect of
NF-𝜅B/IL-6 in colitis associated carcinogenesis are not fully
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Figure 2: Photograph presentation of histological change of dysplasia in the bowels taken from ICRmice dosed with DMH and DSS over the
examined time-points. The images from H&E stained slides showed that tumors were not observed in the controls (Figure 2(a)). However,
dysplastic lesion was observed after induction for 14 weeks (arrow pointed in Figure 2(b)); the degree of dysplasia was further increased after
induction for 16 weeks (arrow pointed in Figure 2(c)) and 18 weeks (arrow pointed in Figure 2(d)) and finally became cancerous lesion after
the induction of 22 weeks (arrow pointed in Figure 2(e)) (Figures 1(a)–1(e): images from H&E stained slides, original magnification ×200).
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Figure 3: Graph analysis of bowel inflammation degree changes
along the neoplastic transformation in ICR mice dosed with DMH
and DSS over examined time-points. The administration of DMH
andDSS for 14 weeks evoked a strong inflammation in the colorectal
mucosa through 16 and 18 weeks and persisted to 22 weeks (𝑃 value
was obtained with the Mann-Whitney U test).
understood thus far. Many factors have been postulated to
be involved in the pathogenesis of CAC [26]. IL-6, as an
important proinflammatory cytokine, has been reported to
be involved in both the tumor initiation and the promotion
stages [12, 32]. In the initiation stage of CAC, IL-6 acts as a
tumor promoter by binding to its gp130-associated receptor
and activated Stat3 signal pathway [12], which is the major
protumorigenic effector for IL-6. Then Stat3 will further
induce the expression of genes that are related to proliferation
and antiapoptosis in transformed cells [12, 20, 33]. Besides
its importance during early tumor promotion, IL-6 can also
accelerate tumor growth during late stages of CAC via a direct
stimulation effect on proliferation and growth of tumor cells
[33, 34]. In addition, IL-6 may function as an amplifier to
stimulate other inflammatory cytokines. For instance, IL-6
is one of the potential stimulators for the differentiation of
Th17 cell [35], while Th17 cell has been demonstrated to be
important in the pathogenesis of both UC and CAC [36].
In addition, the promoting effect of IL-6 on cancer growth
can also be via an activation of NF-𝜅B in the cancer cells
[37]; we have shown that increased NF-𝜅B was expressed
in the transformed epithelial cells and tumor stromal cells
over times and suggested that the interaction between NF-
𝜅B and IL-6 occurred during the procession of CAC in colitis
mice. Thus, multiple mechanisms may be involved in its
protumorigenic effect.
The effect of IL-6 on cellular response is through a
receptor complex consisting of at least one subunit of the
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Figure 4: The expression patterns of IL-6 and NF-𝜅B positive cells in the tumor tissues over examined time-points. Represented
immunohistochemical photos taken from CAC mice treated with DMH and DSS for 18 weeks showed that IL-6 (Figure 4(a)) and NF-𝜅B
(Figure 4(b)) immunoreactivities were observed in both the transformed epithelium (arrow head pointed in Figures 4(a) and 4(b)) and
tumor stroma (arrow pointed in Figures 4(a) and 4(b)). The cell density grading results confirmed the immunohistochemical observations
and demonstrated that the densities of IL-6 (Figures 4(c) and 4(d)) andNF-𝜅B (Figures 4(e) and 4(f)) positive cells in both theCACepithelium
and tumor stroma were significantly increased over examined time-points (white bar for age matched control, black bar for dysplastic
lesion at different examined time-points in Figures 4(c)–4(f)). The western blotting results revealed that both of the IL-6 and the NF-𝜅B
proteins (Figure 4(g)) were increased in dysplastic tumor tissues after induction for 14 weeks and persisted to 22 weeks and confirmed the
immunohistochemical observations as well (A&B: IHC images counterstained with hematoxylin, original magnification 200x; HPF: high
power field; 𝑃 values in Figures 4(c)–4(f) were obtained with the Mann-Whitney U test).
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signal-transducing glycoprotein gp130. The activation of
gp130 is classically through IL-6 binding to a membrane-
bound cognate receptor (IL-6R). However, IL-6 induced bio-
logical activities are largely mediated via a natural formation
of an agonistic complex with soluble IL-6 receptor (sIL-
6R); this complex binds gp130 and then triggers cellular
responses. This activity is termed “IL-6 trans-signaling” and
plays a critical role in promoting chronic inflammation and
inflammation related cancer [33, 38, 39]. Thus, it would be
interesting to further investigate whether blockade of IL-6
trans-signaling can prevent the development of CAC in UC.
Indeed, a humanized anti-IL-6 receptormonoclonal antibody
(tocilizumab) that can block IL-6-mediated signal transduc-
tion by inhibiting IL-6 binding to both the transmembrane
IL-6R and the sIL-6R has been developed [40]. The effi-
cacy of tocilizumab has been confirmed in patients with
chronic inflammatory diseases including Castleman disease
and rheumatoid arthritis [39, 41]; it would be interesting to
investigate whether tocilizumab can inhibit the development
of CAC in the future.
In conclusion, NF-𝜅B/IL-6 pathway as a key protu-
morigenic player is dynamically increased throughout the
pathological process of CAC inmurinemodel.These findings
indicate that NF-𝜅B/IL-6 pathway may contribute to all the
stages of initiation, promotion, and progression of CAC in
colitis mice. Future studies are necessary to fully evaluate
the potential of anti-NF-𝜅B/IL-6 pathway as a preventing
approach (i.e., administered at early stage before dysplastic
transformation) to reduce dysplastic tumor number and as
an intervention approach (i.e., administered after 14weeks) to
suppress the progression of dysplastic degree in this model.
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